 |
|
Novel 4-drug combination proves safe for lung cancer treatment
November 13, 2008Study first to combine 2 chemotherapies and 2 targeted therapies
CHICAGO - The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
Presented today on the press program of the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago, the study is the first to investigate in lung cancer a four-drug regimen of two standard chemotherapies and targeted therapies.
The Southwest Oncology Group (SWOG) Phase II study was led by Edward S. Kim, M.D., assistant professor in M. D. Anderson's Department of Thoracic Head and Neck Medical Oncology. Until now, the SWOG standard regimen for lung cancer has been carboplatin, paclitaxel and Erbitux, explained Kim; with the addition of Avastin, this study looked to increase efficacy without compromising safety.
"We could not conduct a study with four chemotherapeutic agents in patients due to toxicity concerns," said Kim, the study's principal investigator. "The rationale behind the study was the finding that Avastin enhances the efficacy of existing therapy, thereby possibly improving the carboplatin-paclitaxel-Erbitux regimen."
Data in lung cancer has also suggested there's a "synergistic effect" of pairing the epidermal growth factor (EGFR) inhibitor compounds with the vascular endothelial growth factor (VEGF) inhibitor, explained Kim.
Interestingly, explained Kim, the SWOG's study came at a crossroads for lung cancer - soon after a study was presented showing the benefits of adding Avastin to standard chemotherapy, and prior to a study showing a modest survival benefit when Erbitux is combined with chemotherapy.
Between August 2006 and September 2007, the large Phase II study enrolled 110 Stage IIIB or IV non-small cell lung cancer patients, 99 of whom were able to be evaluated. Patients received six cycles of the four-drug regimen, and as maintenance, continued receiving both Avastin and Erbitux. It's unique for a trial to feature a two-drug maintenance biologic therapy combination, explained Kim.
The study met its primary endpoint, safety, defined by frequency of pulmonary hemorrhage, or bleeding, a concern related to Avastin. There were four treatment-related deaths and two due to bleeding, which is consistent with prior Avastin studies, explained Kim. Adverse events such as low blood counts and neuropathy were reported in 40 patients, also consistent with standard chemotherapy.
Secondary endpoints included response rate, progression-free survival and overall survival. Of patients enrolled, 53 percent had shrinkage of their tumors and 24 percent had stable disease. The median progression-free survival rate was seven months and overall survival was 14 months. In contrast, previous SWOG studies showed an average progression-free survival rate of five-and-a-half months and overall survival of 12 months.
"These findings were certainly compelling, and are the best results ever for a SWOG-based study for advanced lung cancer. While early, this four-drug combination seems to show promising, yet modest improvement in efficacy without compromising patients' safety," said Kim. "Our next priority will be to analyze the tissue from this to study to help find appropriate biomarkers for the disease to best understand who might benefit from this drug regimen."
A biomarker analysis of this study is ongoing and a randomized Phase III study is planned, with the trial scheduled to open in 2009.
University of Texas M. D. Anderson Cancer Center
The Southwest Oncology Group (SWOG) Phase II study was led by Edward S. Kim, M.D., assistant professor in M. D. Anderson's Department of Thoracic Head and Neck Medical Oncology. Until now, the SWOG standard regimen for lung cancer has been carboplatin, paclitaxel and Erbitux, explained Kim; with the addition of Avastin, this study looked to increase efficacy without compromising safety.
"We could not conduct a study with four chemotherapeutic agents in patients due to toxicity concerns," said Kim, the study's principal investigator. "The rationale behind the study was the finding that Avastin enhances the efficacy of existing therapy, thereby possibly improving the carboplatin-paclitaxel-Erbitux regimen."
Data in lung cancer has also suggested there's a "synergistic effect" of pairing the epidermal growth factor (EGFR) inhibitor compounds with the vascular endothelial growth factor (VEGF) inhibitor, explained Kim.
Interestingly, explained Kim, the SWOG's study came at a crossroads for lung cancer - soon after a study was presented showing the benefits of adding Avastin to standard chemotherapy, and prior to a study showing a modest survival benefit when Erbitux is combined with chemotherapy.
Between August 2006 and September 2007, the large Phase II study enrolled 110 Stage IIIB or IV non-small cell lung cancer patients, 99 of whom were able to be evaluated. Patients received six cycles of the four-drug regimen, and as maintenance, continued receiving both Avastin and Erbitux. It's unique for a trial to feature a two-drug maintenance biologic therapy combination, explained Kim.
The study met its primary endpoint, safety, defined by frequency of pulmonary hemorrhage, or bleeding, a concern related to Avastin. There were four treatment-related deaths and two due to bleeding, which is consistent with prior Avastin studies, explained Kim. Adverse events such as low blood counts and neuropathy were reported in 40 patients, also consistent with standard chemotherapy.
Secondary endpoints included response rate, progression-free survival and overall survival. Of patients enrolled, 53 percent had shrinkage of their tumors and 24 percent had stable disease. The median progression-free survival rate was seven months and overall survival was 14 months. In contrast, previous SWOG studies showed an average progression-free survival rate of five-and-a-half months and overall survival of 12 months.
"These findings were certainly compelling, and are the best results ever for a SWOG-based study for advanced lung cancer. While early, this four-drug combination seems to show promising, yet modest improvement in efficacy without compromising patients' safety," said Kim. "Our next priority will be to analyze the tissue from this to study to help find appropriate biomarkers for the disease to best understand who might benefit from this drug regimen."
A biomarker analysis of this study is ongoing and a randomized Phase III study is planned, with the trial scheduled to open in 2009.
University of Texas M. D. Anderson Cancer Center
Lung Cancer Current Events and Lung Cancer News RSSResearchers Identify Role of Gene in Tumor Development, Growth and Progression
Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis.
Common pain relief medication may encourage cancer growth
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.
Study raises concerns about outdoor second-hand smoke
Indoor smoking bans have forced smokers at bars and restaurants onto outdoor patios, but a new University of Georgia study in collaboration with the Centers for Disease Control and Prevention suggests that these outdoor smoking areas might be creating a new health hazard.
Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe
The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated.
PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer
A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting.
Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results.
Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer
Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians.
Preventative brain radiation for lung cancer patients: Benefits and risks
A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain.
Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer
A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer.
Intervals between lung cancer diagnosis and treatment displays a health care disparity
Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies.
More Lung Cancer Current Events and Lung Cancer News Articles
 |
How to Survive Lung Cancer - A Practical 12-Step Plan by Michael Lloyd (Author) Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter summaries. |
 |
Lung Cancer: Myths, Facts, Choices--and Hope by Claudia I. Henschke (Author), Peggy McCarthy (Author), Sarah Wernick (Contributor) Winner of the 2003 American Society of Journalists and Authors' June Roth Memorial Award for Health and Medical Books. An authoritative book with new lifesaving strategies for those at risk and those already diagnosed. Lung cancer kills more women than breast cancer, more men than prostate cancer—because it's usually found too late. Claudia Henschke's groundbreaking research on early diagnosis, published in The Lancet, made headlines worldwide. Now, for the first time, she offers specific recommendations based on her latest findings: who needs to be checked, where to be tested, and what to expect. Dr. Henschke and coauthor Peggy McCarthy, a leading patient advocate, provide up-to-the-minute information on diagnosis, treatment, and survival, accompanied by inspiring words from... |
 |
Voices of Lung Cancer: The Healing Companion: Stories for Courage, Comfort and Strength (Voices Of series) by The Healing Project (Editor), S. Epatha Merkerson (Editor) Provided by the patients, their friends, families, and caregivers of those diagnaosed with lung cancer, these very personal stories offer inspired insight into the ways families and professionals care for both themselves and the patient, gain a deeper understanding of the relationships, and learn to come to terms with the end of life. Included are essays by medical experts about the science of lung cancer, current treatments, choosing the right doctors, and what the future holds for the next generation of patients. |
 |
Quick Facts on Lung Cancer by American Cancer Society (Author) Educate yourself about lung cancer What are your risk factors for lung cancer? Can you prevent it? How is lung cancer treated? What should you ask your doctor? QuickFACTS Lung Cancer is both a comprehensive and a quick read, with highlighted cover tabs for quick reference of specific topics. QuickFACTS Lung Cancer: Covers everything from risk factors to living well after cancer treatment Provides critical questions to ask your healthcare team Educates and empowers you right from the start Completely updated with the latest patient treatment guidelines Includes a lung cancer dictionary |
 |
Lung Cancer by Jack A. Roth (Author), James D. Cox (Author), Waun Ki Hong (Author) Lung cancer is a major cause of cancer-related deaths in men and women. However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been made. |
 |
Lung Cancer: Dana-Farber Cancer Institute Handbook (Dana-Farber Cancer Institute Handbooks) by Arthur T. Skarin MD FACP FCCP (Editor), Paul Lorigan MB FRCP (Editor) Written by highly eminent authors, Lung Cancer - a handbook in the Dana-Farber Cancer Institute series - is produced in full color and is richly illustrated throughout, providing a review of each cancer including its incidence, epidemiology, etiology and histopathology, together with the clinical features. Diagnostic studies and current clinical and pathological staging are also given. Detailed tables are provided with histopathological classification, diagnostic studies and, when important, prognostic factors. Current therapies are also discussed in detail, particularly the management of metastatic lung disease in the context of new and emerging treatments. Comprehensive coverage - from risk and prevention, and screening and diagnosis, through to treatment options (surgery,... |
 |
Lung Cancer: Making Sense of Diagnosis, Treatment, and Options by Lorraine Johnston (Author) Lung cancer is the top cancer killer in the U.S. Yet it receives little attention from the media, and those with lung cancer suffer more blame and stigma than other cancer patients, even though 50 percent of them are former smokers or have never smoked. Lung cancer treatments and the daunting prognosis for some types and stages of lung cancer can significantly impact quality of life. In straightforward language, Lung Cancer: Making Sense of Diagnosis, Treatment & Options addresses its readers' medical, emotional, and support needs. The book includes stories from patients themselves, their families and their healthcare professionals. Author and patient advocate Lorraine Johnston emphasizes using knowledge to dispel fear. The content has been reviewed by top medical experts and physicians... |
 |
100 Questions & Answers About Lung Cancer, Second Edition by Karen Parles (Author), Joan H. Schiller (Author) Empower yourself! No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Second Edition enables patients and their families to seek our the best treatment possible for early detection of lung cancer. Providing both the doctor s and patient s point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Second Edition, expert authors use their experiences with patients to provide support and hope to the tens of thousands of people coping with this disease. |
 |
Mom Lung Cancer Support Kids Dark T-Shirt by CafePress |
 |
A Lung Cancer: Principles and Practice by Harvey I Pass (Editor), David P Carbone (Editor), David H Johnson (Editor), John D Minna (Editor), Andrew T Turrisi (Editor) Thoroughly revised and updated, this Third Edition is the most comprehensive, current reference on lung cancer, with contributions from the world's foremost surgeons, radiation oncologists, medical oncologists, pulmonologists, and basic scientists. This edition includes sixteen new chapters and has been reorganized for greater clinical emphasis. Coverage includes complete information on combined modality treatments for small cell and non-small cell lung cancer and on complications of treatment and management of metastases. Emphasis is also given to early detection, screening, prevention, and new imaging techniques. A new editor, David Carbone, provides state-of-the-art coverage of the molecular genetics and biology of lung cancer. |
| © 2009 BrightSurf.com |